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Glucocorticoids (GCs) are steroid hormones predominantly produced in the adrenal
glands in response to physiological cues and stress. Adrenal GCs mediate potent
anti-inflammatory and immunosuppressive functions. Accumulating evidence in the past
two decades has demonstrated other extra-adrenal organs and tissues capable of
synthesizing GCs. This review discusses the role and regulation of GC synthesis in
the intestinal epithelium in the regulation of normal immune homeostasis, inflammatory
diseases of the intestinal mucosa, and the development of intestinal tumors.
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GENERAL ASPECTS OF GLUCOCORTICOIDS
Glucocorticoids
Glucocorticoids (GCs) are immunoregulatory hormones synthesized in the adrenal cortex and
secreted into the blood in a circadian mode under physiological and stress conditions (1). GCs
regulate fundamental body functions in mammals including control of cell growth, development,
metabolic homeostasis, cognition, mental health, immune homeostasis, and apoptosis (2–5).
In the 1940s GCs were discovered as extracts of the adrenal cortex. This was followed by
the isolation of adrenocorticotropic hormone (ACTH) from pituitary gland extracts. In 1950,
Kendall, Reichstein, and Hench were awarded the Nobel Prize in Physiology and Medicine
for their pioneering work in describing that GCs had a powerful anti-inflammatory effect
in the treatment of rheumatoid arthritis (6, 7). Since the 1950s, and owing to their strong
anti-inflammatory and immunosuppressive activities, GCs have been widely used for the treatment
of inflammatory disorders and autoimmune diseases, such as asthma, rheumatoid arthritis,
dermatitis, inflammatory bowel disease (IBD), sepsis, lupus erythematosus, and multiple sclerosis
(7–11). GCs are also used as immunosuppressive drugs following organ transplantation and in the
treatment of leukemia (11, 12).
Immunological, environmental, and emotional stress induces the release of GCs to mediate
immunoregulatory activities, mostly immunosuppressive, on distant tissues and cells, in particular
in immune cells (4). For example, GCs have an immunosuppressive activity on T cell-mediated
immune responses (13) and this is why they are frequently used for the treatments of
T cell-mediated immunopathologies.
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The synthesis of adrenal GCs is regulated by the
hypothalamic-pituitary-adrenal (HPA) axis (Figure 1), and
controlled by the main circadian oscillator located in the
suprachiasmatic nucleus (SCN) of the hypothalamus (1). Basal
and stress-inputs to the hypothalamus promote the release of
corticotropin-releasing hormone (CRH) from neurosecretory
cells of the paraventricular nucleus (PVN), which stimulates
the synthesis and secretion of ACTH (corticotropin) from the
anterior pituitary gland. ACTH in turn promotes the production
and secretion of GCs (cortisol in humans and corticosterone in
rodents) from the adrenal cortex (14) (Figure 1). Afterwards,
GCs target the hypothalamus and the anterior pituitary to
inhibit the release of CRH and ACTH in a negative feedback
loop (Figure 1). GCs act on almost all types of cells in the
body to maintain homeostasis both, in response to normal
diurnal changes in metabolism and in response to stress (2, 3).
Noteworthy, inflammatory cytokines including interleukin-1
beta (IL-1β), IL-6, and tumor necrosis factor alpha (TNF) were
also reported to stimulate the release of ACTH and CRH further
indicating the bidirectional communication between immune
and neuroendocrine systems (15).
Adrenal GC Synthesis
Adrenal GCs are synthesized and released by the zona fasciculata
of the adrenal cortex in a circadian manner, as well as in
response to environmental and immunological stress (16).
GCs are synthesized from the precursor cholesterol and the
synthesis is regulated by the transcriptional control of the
steroidogenic enzymes that involve cytochrome P450 (CYP)
oxidative enzymes and hydroxysteroid dehydrogenase (HSD)
enzymes (1) (Figure 1). The first step in steroidogenesis takes
place within mitochondria, where cholesterol is transported
from the outer to the inner mitochondrial membrane by the
steroidogenic acute regulatory protein (StAR) (17). The first
and rate-limiting step in steroid synthesis is the conversion of
cholesterol to pregnenolone by the action of side-chain cleavage
enzyme, P450scc, encoded by the CYP11A1 gene (Figure 1).
Abbreviations: ACTH, Adrenocorticotropic hormone; AF-1, activation function
1; AP-1, activator protein 1; APC, Adenomatous polyposis coli; cAMP, cyclic
adenosine monophosphate; CD, Crohn’s disease; CREB, cAMP response element
binding protein; CRH, corticotropin-releasing hormone; CTL, cytotoxic T
lymphocyte; CTLA-4, CTL-antigen 4; CYP, cytochrome P450; DBD, DNA-
binding domain; DC, dendritic cell; DLPC, dilauroyl phosphatidylcholine; DSS,
dextran sulfate sodium; GC, Glucocorticoids; GILZ, glucocorticoid-induced
leucine zipper; GR, glucocorticoid receptor; GRE, GC response element; HPA,
Hypothalamus-pituitary-adrenal (gland); HSD, hydroxysteroid dehydrogenase;
IBD, Inflammatory Bowel Disease; IEC, intestinal epithelial cell; IEL, intraepithelial
lymphocyte; IFN-γ, interferon gamma; ISC, intestinal stem cell; LCMV,
lymphocytic choriomeningitis virus; LBD, ligand-binding domain; LPL, lamina
propria lymphocyte; LRH-1, liver receptor homolog-1; MAPK, mitogen activated
protein kinase; MC, mineralocorticoid; NF-κB, nuclear factor “kappa-light-chain-
enhancer” of activated B cells; NR, nuclear receptor; NR5A1, nuclear receptor
subfamily 5 group A member 1; PD-1, programmed death-1; PMA, phorbol
myristate acetate; PPARγ, peroxisome proliferator-activated-receptor gamma;
PVN, paraventricular neuron; SCN, suprachiasmatic nucleus, SF-1, steroidogenic
factor 1; SHP, small heterodimer partner; StAR, steroidogenic acute regulatory
protein; STAT, signal transducer and activator of transcription; TCR, T cell
receptor; TEC, thymic epithelial cell; TF, transcription factor; TGF, transforming
growth factor; TJ, Tight junction; TNBS, 2,4,6-trinitrobenenesulphonic acid; TNF,
tumor necrosis factor; TNFR, TNF-receptor; UC, ulcerative colitis.
Thus, it is the expression of P450scc that renders a cell
steroidogenic, i.e., able to synthesize steroids de novo. Supporting
this notion, mice with a deletion of the Cyp11a1 gene suffer
from steroid deficiency (17–19). In humans, once pregnenolone
is produced from cholesterol, it undergoes 17α-hydroxylation
by P450c17 (CYP17) to yield 17α-hydroxypregnenolone. Next,
pregnenolone is converted to progesterone by 3β-HSD (20).
Afterwards, 21-hydroxylase (CYP21) converts progesterone into
11-deoxycortisol (humans) or 11-deoxycorticosterone (rodents),
then 11β-hydroxylase encoded by the CYP11B1 gene catalyzes
the last hydroxylation step in the GC synthesis. The last
step comprises the conversion of 11-deoxycortisol to cortisol
in humans, and 11-deoxycorticosterone to corticosterone in
rodents, since the rodent adrenals lack CYP17 enzyme (20,
21) (Figure 1).
Several factors have been shown to contribute to and modify
the cellular and organismal responses to GCs. Notably, most of
the secreted cortisol in the blood (∼90%) is bound to proteins
(corticosteroid-binding globulins and albumin). This binding
regulates the general availability of GCs to tissues and/or direct
the delivery of hormones to specific sites (22–24).
It is known that the presence of an 11β-hydroxyl group
is essential for the anti-inflammatory and immunosuppressive
effects of GCs and for the sodium-retaining effects of the
mineralocorticoids (MCs). Therefore, it has been shown that the
isoenzymes of 11β-hydroxysteroid dehydrogenase (11β-HSD)
critically regulate the conversion between the active and the
inactive form of a steroid in target cells. 11β-HSD2 catalyzes the
conversion of cortisol, the biologically active form, to the inactive
cortisone, whereas 11β-HSD1 converts cortisone to cortisol.
Thus, 11β-HSD1, which is expressed in a wide range of tissues
and predominantly in the liver, facilitates GC hormone actions
whereas the major role of 11β-HSD2 is to prevent cortisol from
gaining access to high-affinity MC receptors. Therefore, 11β-
HSD2 is predominantly expressed in the MC responsive cells of
the kidney and other MC target tissues such as the colon (11).
Adrenal GC synthesis is regulated by the orphan nuclear
receptor (NR) steroidogenic factor 1 (SF-1), encoded by the
NR5A1 (nuclear receptor subfamily 5, group A, member 1)
gene. SF-1 plays a key role in the development and function
of steroidogenic tissues, and has emerged as a key regulator of
endocrine function within the hypothalamic-pituitary-gonadal
axis and adrenal cortex, and as an essential factor in sex
differentiation. SF-1 was first identified as an essential regulator
of endocrine development and function, including steroid
hormone biosynthesis, via induction of the expression of
steroidogenic enzymes, including CYP11A1, CYP17, CYP21,
CYP11B1, and 3β-HSD. Similarly, SF-1 has been reported
to regulate the expression of StAR as well as the ACTH
receptor (25, 26).
Glucocorticoid Receptor Activation
GCs act via genomic (transcriptional) and non-genomic
(transcription-independent) mechanisms (27). Most cellular
actions of GCs are primarily mediated via binding to their
cognate intracellular receptor, the classic glucocorticoid receptor
(GR) protein, GRα. GR is a ligand-regulated transcription factor
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FIGURE 1 | The HPA-axis and adrenal glucocorticoid synthesis. The Hypothalamus-pituitary-adrenal-axis (also known as “stress axis”) represents the sequence of
endocrine events between the hypothalamus (green), the anterior pituitary gland (blue), and the cortex of the adrenal gland (red). Corticotropin-releasing
hormone (CRH) secreted from the paraventricular neurons (PVNs) of the hypothalamus stimulates adrenocorticotropic hormone (ACTH, corticotropin) release from the
anterior pituitary, which consequently stimulates the production of glucocorticoids in the steroidogenic cells of the zona fasciculata in the adrenal cortex. Blue lines
indicate negative feedback. The right-hand panel shows the biochemical reactions leading to glucocorticoid-synthesis in humans and in rodents. The synthesizing
enzymes are shown in yellow (and light-red for the human CYP17). The (so far known) subcellular localization of the steroidogenic enzymes in the mitochondria or the
ER is highlighted by dotted-line boxes.
(TF) that belongs to the NR subclass 3C and is therefore known
as NR3C1 (nuclear receptor subfamily 3, group C, member 1).
In line with the pleiotropic actions of GCs, GR is expressed in
nearly every cell of the body and is essential for life after birth.
Alternative mRNA splicing results in a second GR isoform, GRβ.
GRβ does not bind to GC agonists, resides constitutively in the
nucleus, and is inactive by itself. However, when co-expressed
with GRα, GRβ functions as a dominant negative inhibitor of
GRα (2, 28–31).
The GRα shares common structural and functional domains
with other NRs. These domains include an N-terminal ligand-
independent transactivation domain, also called activation
function 1 (AF-1), which is responsible for the transcription
activation, a highly conserved DNA-binding domain (DBD)
that is important for GR homodimerization and DNA-binding
specificity, a C-terminal ligand-binding domain (LBD) that
contains the ligand-binding site and a second ligand-dependent
transactivation domain (AF-2), and a flexible hinge region
separating the DBD and the LBD (32–34). In addition to the
known dimerization function of the DBD, in vivo evidence
has shown that LBD mutation severely compromised GR
dimerization, whereas no correlation between oligomerization
state, DNA binding, and transcriptional activity could be
established (35). These data clearly indicate that multiple
domains are involved in GR dimerization.
In the absence of ligand, the GRα is sequestered
predominantly in the cytoplasm as an inactive multi-protein
complex formed by chaperonic molecules, including heat shock
proteins Hsp90, Hsp70, Hsp23, and immunophillins p59 and
calreticulin (28, 29, 36). These proteins maintain the receptor in
a conformation that is transcriptionally inactive, but favors high
affinity ligand binding (2). Binding of endogenous or synthetic
GCs to the LBD of GRα induces receptor conformational change
leading to the dissociation of the multi-protein complex and
allows the translocation of the GC/GR complex to the nucleus
where it regulates gene transcription (21). Upon translocation
to the nucleus, the GRα binds DNA sequences, known as GC
response elements (GREs), to positively or negatively regulate
Frontiers in Immunology | www.frontiersin.org 3 June 2019 | Volume 10 | Article 1438
Ahmed et al. GCs and Intestinal Immune Homeostasis
gene transcription by direct DNA-binding or by interaction with
other proteins (3, 37).
In addition to the transcription activation, the GR represses
a wide variety of genes. This repression function is mediated by
negative GREs (nGRE) in the promoter regions of target genes.
nGREs contribute to the negative feedback of HPA axis, bone,
and skin function, inflammation, angiogenesis, and lactation.
Moreover, GR inhibits glycoprotein hormone promoter, which
is positively regulated by the cyclic adenosine monophosphate
(cAMP) response element binding protein (CREB) and contains
binding sites for CREB and GR. Upon DNA binding, GR inhibits
transcription activation directly by preventing CREB binding
(28, 38, 39).
Accumulating evidence suggests that GCs can act via non-
genomic mechanisms to elicit more rapid cellular responses
(within seconds to minutes) that do not require nuclear
GR-mediated changes in gene expression. The non-genomic
effects of GCs are considered to be mediated through binding
to membrane-bound GR, binding to cytosolic GR, or by
interactions with cellular membranes (30, 40, 41). Bartholome
et al. showed that membrane GRs are expressed in human
monocytes and B cells (42). Additionally, they monitored a
strong positive correlation between the frequency of membrane
GR-positive monocytes and various parameters of disease
activity in patients with rheumatoid arthritis. This observation
prompted the authors to suggest that immunostimulation
induces the expression of membrane GR in immune cells such
as monocytes that in turn triggers rapid signal cascades leading
to a significantly higher percentage of cells to undergo GC-
induced apoptosis to limit excessive immune reaction (42).
GCs can also bind to their cytosolic GR to induce rapid non-
genomic effects resulting in interactions with signaling pathways.
For example, GCs were shown to activate endothelial nitric
oxide synthase in a non-genomic manner and mediated by
stimulated phosphatidylinositol 3-kinase and protein kinase Akt
phosphorylation (41, 43). High concentrations of GCs have been
shown to induce quantitative increase in the intercalation of GC
molecules in the membrane, influencing the membrane fluidity,
membrane associated proteins and cation uptake, as measured by
the reduction of cation transport ATPase activity (44, 45).
Glucocorticoid Functions
Anti-inflammatory Functions of GCs
Upon tissue injury, irritants or pathogen invasion, immune
cells of the innate, and adaptive immune systems are activated
and recruited to the site of inflammation (12, 46). Immune
cells activation and recruitment is mediated by cytokines and
chemokines, which are regulated by inflammatory TFs, including
the nuclear factor ’kappa-light-chain-enhancer’ of activated B-
cells (NF-κB), signal transducer and activator of transcription
proteins (STATs) and activator protein 1 (AP-1) (46). These TFs
are crucial regulators of a variety of cellular functions, including
cell survival, proliferation, differentiation, and apoptosis (47–50).
In the presence of pro-inflammatory stimuli, these TFs trigger
activation of pro-inflammatory cytokines, such as TNF, IL-1β,
and IL-6 among others, to induce inflammation and promote cell
survival (51). GR induces anti-inflammatory activities by direct
interaction with other TFs, including NF-κB (51), STAT3 (52),
STAT5, and AP-1, leading to their inhibition, thus repressing the
expression of pro-inflammatory genes and thereby promoting the
resolution of inflammation (29) (Figure 2). Since this interaction
does not require DNA binding, the term tethering GRE is often
used to describe these elements. Interestingly, tethering GREs
do not contain DNA binding sites for GRs, but instead contain
binding sites for other DNA-bound regulators, including NF-κB
and AP-1, that recruit GRs (28, 53).
GCs also induce proteins with anti-inflammatory activities,
including glucocorticoid-induced leucine zipper (GILZ),
resulting in the inhibition of the mitogen-activated protein
kinase (MAPK) pathway (27). MAPK activation is associated
with cell proliferation, differentiation, migration, senescence and
apoptosis [reviewed in (54)]. Another mechanism, by which
GILZ dictates its anti-inflammatory function, is via inhibition of
NF-κB and AP-1 activities (27, 55).
Immunosuppressive and Metabolic Functions of GCs
GCs have powerful immunosuppressive activities mediated by
acting on almost all types of cells, in particular on immune cells
(33). GCs induce apoptosis in a variety of immune cells, including
developing thymocytes as well as circulating and tissue-resident
T cells, mediated by the pro-apoptotic proteins Puma and Bim
(56–58). GCs also promote dendritic cell (DC) apoptosis (29).
Additionally, GCs favor the expansion of immunosuppressive
regulatory T cells (Tregs) by upregulating the expression of
FoxP3, the master regulator of Tregs (59, 60). Moreover, GCs
promote the shift from T helper 1 (Th1) to Th2 immune
responses by differentially regulating apoptosis of Th1 and Th2
cells (13, 61–63).
GCs also control the function of innate immune cells,
including monocytes and macrophages, in order to regulate
tissue homeostasis. GCs have been shown to induce the
differentiation and promote the survival of anti-inflammatory
(M2) macrophages, evident by the induced expression of the
immunomodulatory cytokine IL-10. This effect is mediated
by prolonged activation of the MAPK pathway resulting in
inhibition of caspase activities, and expression of anti-apoptotic
genes. On the other hand, GCs efficiently suppress classical pro-
inflammatory macrophage (M1) activation, as evidenced by the
inhibition of the pro-inflammatory cytokines TNF, interferon
gamma (IFNγ) and IL-1β (64–67) (Figure 2). These cytokines
are highly upregulated inmany inflammatory disorders, and their
crucial role in the pathogenesis of IBD is well-established (68, 69).
GCs potently inhibit the differentiation of DCs and their capacity
to stimulate T cells (70, 71).
The resulting immune reaction in pathophysiological
conditions depends on the balance between effector cells
promoting inflammation and its modulation by regulatory
mechanisms (72). In this context, the discussed anti-
inflammatory and immunosuppressive properties of GCs
are necessary to restore homeostasis following successful
elimination of the injurious agent, ultimately leading to the
resolution of inflammation and tissue repair after tissue damage
caused by excessive inflammation (12).
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FIGURE 2 | TNF and intestinal GC synthesis. Intestinal epithelial barrier disruption leads to permeability defects and the subsequent interaction of intestinal immune
cells with the luminal contents. Activated immune cells release pro-inflammatory cytokines, such as TNF. In turn, TNF results in tight junction (TJ) disruption and
intestinal epithelial cell (IEC) apoptosis and thereby exacerbates local inflammation. TNF also directly stimulates IECs to synthesize and release immunoregulatory
glucocorticoids (GCs) to counter-balance excessive tissue damage. GCs act via the glucocorticoid receptor (GR) to inhibit TNF-mediated tissue damage in a negative
feedback loop. The GR also inhibits pro-inflammatory transcription factors, including NF-κB, AP-1, and STATs leading to the resolution of the inflammation.
Another main biological function of adrenal GCs includes
the control of energy metabolism and glucose homeostasis. GCs
promote gluconeogenesis in the liver and decrease glucose uptake
by antagonizing the response to insulin. Whereas, physiological
levels of GCs are required for proper metabolic control, excessive
GC action has been linked to a variety of metabolic diseases, such
as type II diabetes and obesity (73, 74).
EXTRA-ADRENAL GC SYNTHESIS
Overview of Extra-Adrenal GC Synthesis
The substantial capacity of the adrenal glands to produce
enormous amounts of GCs and to release them into the systemic
circulation in response to stress hampered the discovery of
other GC-producing organs. In fact, strong systemic immune cell
activation upon removal of the adrenal glands in mice results
in rapid death due to shock (75). Therefore, for long time GC
synthesis and secretion was thought to be exclusively confined
to the adrenal glands. However, increasing evidence has shown
that other extra-adrenal organs are also capable of producing GCs
[reviewed in (76)]. Evidence for local GC synthesis comprises
the detection of steroidogenic enzymes and high levels of local
GCs in different tissues, even upon adrenalectomy. Moreover,
the physiological relevance of local GC synthesis has been shown
by the major impact of the inhibition of local GCs synthesis
even in adrenal-intact scenarios (76–79). Thus, whereas systemic
adrenal-derived GCs coordinate multiple organ functions and
whole body metabolism, locally synthesized GCs play a highly
specific role in regulating local homeostasis, cell development
and immune cell activation (31, 80).
In the past two decades the thymus (81–83), the skin
(84, 85), the brain (78), the vasculature (86), the lung
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(79), and the intestine (77, 87–90) have been shown to
produce substantial amounts of GCs, and thereby regulate local
immunological responses.
Pioneering work by the group of Ashwell in the thymus
provided the first proof for extra-adrenal GC production and
opened an exciting field of research for the identification of other
GC-producing organs (83). They showed that bioactive GCs
are de novo synthesized by thymic epithelial cells (TECs), and
that they play an important role in antigen-specific thymocyte
development by opposing cell death induction from too strong
TCR signaling during negative selection, thereby allowing
positively selected T cells to survive. This is supported by
the finding that inhibition of thymic corticosterone production
increased TCR activation-induced cell death and enhanced
negative selection of thymocytes (13, 58, 83). Of note, thymocytes
(91) and mature T cells (92, 93) were also reported to synthesize
GCs, yet it is presently unclear whether this reflects de novo
synthesis or conversion of serum-derived inactive derivatives.
Interestingly, the skin locally produces CRH, ACTH and
expresses the steroidogenic enzymes. Therefore, the skin is
considered to have its own local HPA axis. De novo synthesis
of GCs in the skin is thought to play an important role in local
homeostasis as indicated by the deficiency of the steroidogenic
enzymes in skin biopsies from patients with inflammatory skin
diseases (94). Other organs that express the GC-synthesizing
machinery and therefore are capable to de novo synthesize
bioactive GCs from cholesterol include the brain, the vasculature
and the intestine (95). Interestingly, although the lung expresses
all the steroidogenic enzymes required for de novo synthesis,
analysis of lung GC synthesis revealed that the predominant
pathway by which corticosterone is produced is by reactivation
from inactive serum-derived dehydrocorticosterone via 11β-
HSD1 enzyme (79).
Differential Modes of Synthesis of
Extra-Adrenal GCs
Most of extra-adrenal GC-synthesizing organs express both
the enzymes required for de novo GC synthesis as well as the
reactivating enzymes from inactive metabolites. However,
interestingly different extra-adrenal organs synthesize
bioactive GCs via different mechanisms, possibly reflecting
local environmental needs. For example, TECs have been
shown to have the mRNA, protein, and activities of enzymes
required for de novo GC synthesis, including StAR, CYP11A1,
3β-HSD, CYP17, and CYP11B1. Furthermore, fetal thymic
organ culture demonstrated the conversion of a cholesterol
analog to pregnenolone and 11-deoxycorticosterone. Similar
to adrenal GCs, TEC-derived GC synthesis was stimulated by
ACTH (76, 83). In contrast, ACTH inhibited GC synthesis in
thymocytes by downregulation of Cyp11b1 mRNA expression.
This opposite effect of ACTH in thymocytes is not yet fully
understood but could possibly represent a function to limit
damage to the gland by down-regulating GC synthesis during a
strong activation of the HPA axis (91).
Like the thymus, the skin mainly synthesizes GCs de novo
under the control of the local HPA axis, and the synthesis is
regulated by several factors including ACTH, CRH and IL-1β
(85). Noteworthy, the skin neuroendocrine system is able to
crosstalk with the systemic HPA axis and thus with the adrenal
GC synthesis. Interestingly, although the skin also expresses the
reactivating enzyme 11β-HSD1, GC reactivation by keratinocytes
seems to play a minor role in immune cell activation and contact
hypersensitivity compared to the essential role of the de novo
synthesized GCs. The reason for this could be due to its large
dependence on the availability of the GC metabolite from the
circulation (94).
As mentioned before, the lung largely depends on the
reactivation pathway for generating bioactive GCs. Our
group reported that upon immune cell activation by
lipopolysaccharide (LPS) or anti-CD3 antibody increased
production of corticosterone in ex vivo lung cultures was
observed (79). Interestingly, only Cyp11a1 has been shown
to be upregulated whereas other steroidogenic enzymes
expression remained unchanged. Strikingly, whereas Hsd11b1
gene was strongly upregulated, Cyp11b1 was barely detectable
indicating that reactivation of serum-derived inactive metabolite
(dehydrocorticosterone) is a more prominent pathway of local
GC synthesis in the lung. In line with this, adrenalectomized
mice failed to produce local GCs in the lung upon immune cell
activation. This finding further supports the dependence of lung
GC synthesis on adrenal GCs (79).
Our group also described and characterized the de novo
synthesis of intestinal GCs for the first time. In the intestinal
mucosa, GC-synthesizing enzymes were detected at low levels,
however, they were strongly upregulated in response to
immunological stress resulting in the detection of corticosterone
in the supernatant of ex vivo cultured intestinal tissue (77).
Recently, we also demonstrated a relevance for the GC
reactivation impairment in the pathogenesis of IBD (96). In this
review, we will discuss the synthesis of GCs in the intestine in
more detail.
Taken together, it seems that various extra-adrenal organs
synthesize GCs differently in order to cope with local
immunological stress and to regulate local immune homeostasis.
INTESTINAL EPITHELIAL STRUCTURE
AND HOMEOSTASIS
The intestinal epithelium represents the largest mucosal surface
in the human body covering an area of almost 200 m2 (21).
This surface represents the physical barrier that separates the
epithelium not only from potential pathogens and food antigens
but also from harmless commensal bacteria termed microbiota
(97, 98). The gut is anatomically divided into the small intestine
and the colon. The small intestine can be subdivided into the
duodenum, the jejunum, and the ileum. The architecture of the
intestine is organized into crypts of Lieberkühn and epithelial
protrusions, called villi, in the small intestine, whereas the colon
consists mainly of crypts and has no villi, but a flat surface
instead (99, 100). The main function of the epithelium is water
and nutrient absorption and the maintenance of effective barrier
function in order to maintain tissue homeostasis (101, 102). The
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intestinal epithelium promotes these functions by a single layer of
intestinal epithelial cells (IECs) organized along the crypt-villus
axis (99, 103). IECs are constantly regenerated from intestinal
stem cells (ISCs) at the bottom of the crypt columnar cells. The
intestinal epithelium has a higher self-renewal rate than any other
mammalian tissue, with a fast turnover of <5 days (104–106).
ISCs give rise to transient amplifying daughter cells that migrate
upward while differentiating into one of the specialized epithelial
lineages (100). This fast proliferation of IECs is eventually
balanced by cell death resulting from loss of attachment at the
tip of the villus followed by subsequent shedding of apoptotic
cells into the lumen, a process known as anoikis (106). The
differentiated epithelial cell types include absorptive enterocytes,
secretory cells (Paneth cells, goblet cells, enteroendocrine cells,
and tuft cells), and the M cells of Peyer’s patches (105). Paneth
cells escape the upwardmigration andmigrate downward instead
to constitute the niche for ISCs (107). These cells secrete anti-
microbial peptides to prevent bacterial infection (103), whereas
tuft cells act as sensors for luminal contents (108). Additionally,
enteroendocrine cells secrete various hormones to coordinate
digestion and metabolism (108).
Contributing to the effective physical and biochemical barrier
function is the mucus secreted by goblet cells, anti-microbial
proteins that eliminate bacteria penetrating the mucous and
IgA secreted by lamina propria plasma cells, in addition to
the tight junctions (TJ) proteins. These TJ are junctional
complexes that connect epithelial cells to each other and thereby
forming tight intracellular seals (109, 110). The intestinal mucosa
also produces high levels of the immunosuppressive cytokines
transforming growth factor beta (TGFβ) and IL-10 to maintain
local homeostasis. In fact, TGFβ- and IL-10-deficient mice
develop spontaneous inflammation (111, 112).
IECs separate the intestinal lumen containing 1014 gut
microbiota cells from the underlying lamina propria and the
rest of the body (113, 114). In addition to the microbiota,
the gut epithelium hosts the largest number of immune cells
in the body (115). These immune cells include the so-called
intraepithelial lymphocytes (IELs) (116), resident macrophages,
DCs, plasma cells, lamina propria lymphocytes (LPLs), and
neutrophils (115, 117, 118). This direct contact of immune cells
with the microbiota, that has great potential to provoke immune
cell stimulation, requires fine-tuning to find the appropriate
balance between protective immune responses and tolerance
toward the microbiota. Disruption of the intestinal epithelial
barrier leads to permeability defects, and subsequent interaction
between luminal microorganisms and cells of the immune system
(Figure 2). The barrier breakdown exacerbates inflammation
leading to severe tissue damage, as in the case of IBD (98).
IBD comprises a group of intestinal inflammatory disorders,
namely ulcerative colitis (UC) and Crohn’s disease (CD).
Although the etiology is currently not fully understood, it has
been associated with a complex interaction between the host
genetics, environmental or microbial factors and the immune
system (119–121). These interactions result in chronic relapsing
inflammation of the intestine as a consequence of inappropriate
immune cell activation (117). UC causes inflammation of
the mucosa of the colon and rectum, whereas CD causes
inflammation of the full thickness of the bowel wall and may
involve any part of the digestive tract from the mouth to the
anus (122).
Chronic inflammation has emerged as one of the hallmarks
of cancer. Many cancers arise following prolonged inflammation
or display inflammatory characteristics throughout progression
(123, 124). For example, the relative risk of colorectal cancer in
patients with IBD has been estimated to increase by up to 20-fold
(125, 126). Notably, the risk correlates directly with the duration
and extent of inflammation (127, 128).
Increasing lines of evidence have shown that the synthesis
of GCs by IECs plays an important role in the regulation
of intestinal immune homeostasis under pathophysiological
conditions (21, 77, 129, 130). Supporting this notion, defective
local intestinal GC synthesis or metabolism has been shown
to be involved in the pathogenesis of intestinal inflammation
(90, 96, 131, 132).
EXTRA-ADRENAL GLUCOCORTICOIDS IN
THE INTESTINE
First evidence for the steroidogenic potential of the gut was
suggested in 1995 following the detection ofCyp11a1 andHsd3b1
mRNA in the gut of mouse embryos by in situ hybridization
(133). Further evidence originated from our own work while
studying IEL apoptosis. It was observed that IELs rapidly
undergo apoptosis when cultured ex vivo, an effect that was
accelerated following GC treatment in mice. Interestingly, while
adrenalectomy significantly reduced IEL ex vivo apoptosis, a
stronger effect was observed upon in vivo administration of the
GR inhibitor RU-486. This observation prompted us to speculate
that another source of GCs, likely in the intestinal mucosa,
primed the IELs already in vivo to undergo ex vivo cell death (56).
Subsequent studies characterized the de novo GC synthesis
in the murine intestinal mucosa in response to immunological
stress following anti-CD3 injection or viral-activated T cells
(77). It was shown that the intestinal mucosa constitutively
expressed many of the steroidogenic enzymes required for the
de novo synthesis of corticosterone from cholesterol and for
the reactivation of corticosterone from dehydrocorticosterone.
Moreover, expression of the steroidogenic enzymes including
Cyp11a1, Cyp11b1, and Hsd11b1 was strongly induced upon
immunological stress. The source of the aforementioned three
enzymes and therefore intestinal GCs was shown to be the crypt
region of the IECs (77). This was demonstrated by a further study
that linked the expression of Cyp11a1 and Cyp11b1 to the cell
cycle, thus restricting the production of GCs to the proliferating
cells of the intestinal crypts (134).
The basal expression of steroidogenic enzymes might suggest
that GC production, though at very low levels, is possibly
fulfilling an important function in the regulation of local immune
homeostasis and epithelial barrier integrity (75). In line with this,
in vitro data revealed the importance of GCs in the maturation
and differentiation of the IECs (135). Additionally, GCs have
been shown to play a role in the expression of TJ proteins and
the maintenance of the intestinal epithelial barrier integrity, in
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particular antagonizing the TJ-destructing effect of TNF during
inflammation (109) (Figure 2).
Cima et al. used adrenalectomized mice to exclude
the contribution of systemic GCs, and measured by
radioimmunoassay the corticosterone release into the
supernatant of ex vivo cultured intestinal tissue from anti-
CD3-injected mice (77). The in situ corticosterone synthesis
was confirmed since metyrapone, a potent inhibitor of 11β-
hydroxylase and 11β-HSD1 (136, 137), blocked corticosterone
release (77). Similarly, stimulation of the innate immune system
with LPS induces GC synthesis in a macrophage-dependent
manner, since it also occurred in RAG−/− mice lacking T
and B lymphocytes (89). Furthermore, administration of TNF,
infection of mice with viruses, or chemically induced intestinal
inflammation promote the expression of Cyp11a1 and Cyp11b1,
and strongly induces the synthesis of intestinal GCs (95).
Although most of the studies of GC synthesis were conducted
in mice, subsequent research showed that the human intestinal
tissue also expresses the steroidogenic enzymes and is capable of
synthesizing GCs (96, 138–140).
Intestinal GC Triggers and the Role of TNF
TNF is a pro-inflammatory cytokine with a wide range of
pleiotropic functions. TNF interacts with two different receptors,
designated TNF receptor (TNFR) 1 and TNFR2, which are
differentially expressed on cells and tissues, and initiate both
distinct and overlapping signal transduction pathways. These
diverse signaling cascades lead to a range of cellular responses,
which include cell death, inflammation, survival, differentiation,
proliferation, and migration (141, 142). In the intestinal
epithelium, TNF demonstrates variable and very complex
functions in physiological as well as pathological conditions
(143). TNF has been shown to drastically promote epithelial
cell death (144) and increase the epithelial barrier permeability
via a direct effect on the expression and organization of TJ
proteins, thereby leading to intestinal inflammation (Figure 2).
In fact, TNF is considered as one of the most important effector
molecules in the pathogenesis of IBD (145). Moreover, TNF
signaling has been shown to drive colonic tumor formation after
sustained chronic colitis. Consequently, TNFR deficiency or the
treatment of wild type mice with the specific pharmacological
inhibitor of TNF, etanercept, markedly reduces colitis-associated
colon cancer (146).
Although the main cellular source for TNF is immune cells,
fibroblasts and epithelial cells have also been shown to produce
TNF (147). Macrophage and T cell activation results in massive
release of TNF, which contributes to the damage of the epithelial
layer (148). Therefore, TNF-neutralizing antibodies have been
efficiently used for the treatment of IBD (142, 149). This is
mainly due to inhibition of IEC cell death, but also due to
the downregulation of pro-inflammatory processes that might
contribute to local tissue damage (101) (Figure 2).
Despite the well-characterized pro-inflammatory properties
of TNF, accumulating evidence for anti-inflammatory roles of
TNF is increasingly appreciated. For example, Naito et al.
demonstrated that the absence or neutralization of TNF in
a mouse model of dextran sulfate sodium (DSS)-induced
colitis exacerbated intestinal inflammation (150). Further studies
revealed that TNF induces intestinal GC synthesis by direct
activation of IECs, thus contributing to intestinal immune
homeostasis. In this regard, TNF plays an anti-inflammatory role
(90) that could be in part through sensitizing activated T cells
to undergo apoptosis, thus resulting in accelerated resolution
of the inflammation (151). Interestingly, TNF seems to be the
master regulator of intestinal GC synthesis irrespective of the
trigger (Figure 2). Noti et al. investigated the intestinal GC
synthesis following macrophage and T cell activation in TNFR-
deficient and wild type mice. They showed that, while immune
cell activation resulted in robust induction of intestinal GCs
in wild type mice, it was significantly decreased in TNFR-
deficient mice (89). Similarly, intestinal GC synthesis was
lacking in mice with TNF deficiency or in TNFR-deficient
mice treated with the inflammatory agent DSS or the hapten
2,4,6-trinitrobenzenesulphonic acid (TNBS). In marked contrast,
oxazolone, a hapten that promotes a Th2 cytokine-mediated
intestinal inflammation that does not involve TNF, fails to
promote intestinal GC synthesis (90). These observations clearly
indicate that inflammation per se is not sufficient to promote
intestinal steroidogenesis, but rather the type of inflammation
appears to be critical. It also points out the dependence of
intestinal GC synthesis on TNF (90, 95).
Taking into consideration the mutual antagonistic action of
TNF and GCs, this GC-regulatory function of TNF might appear
confusing at a first glance. Nevertheless, local intestinal GC
synthesis may counterbalance the deleterious effects of TNF in
two ways: (1) an increase in barrier resistance by promoting the
expression of TJ proteins and (2) by dampening overwhelming
immune responses and the associated immune cell activation that
are triggered by epithelial barrier disruption. Hence, although
TNF is involved in the disruption of the epithelial barrier
integrity, it is also involved in restoring intestinal epithelial
barrier function by the induction of GC synthesis as a negative
feedback loop (Figure 1). Moreover, since TNF is not only
produced by immune cells but also by IECs, it is feasible to
believe that this regulatory systemmay even work in an epithelial
layer-autonomous manner (75, 89).
Taken together, TNF seems to function as a sensor of
intestinal immune responses and a master regulator of intestinal
GC synthesis in response to activation of the innate and
adaptive immune system. Furthermore, TNF mediates a novel
anti-inflammatory function via the induction of intestinal GC
synthesis (89) (Figure 2).
Intestinal GCs Functions
Under steady-state conditions, GCs have been implicated in
the maturation and the maintenance of the intestinal epithelial
barrier integrity. For instance, results from in vitro experiments
revealed that synthetic GCs had a protective effect against the
TNF-dependent increase of intestinal permeability. Microarray
data analysis demonstrated that GCs differentially regulate the
expression of enterocyte markers that are involved in the
polarization and TJ formation (152).
Given the potent immunoregulatory activities of GCs, extra-
adrenal GC synthesis in the intestine is assumed to play an
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important role in the regulation of local immune homeostasis.
Indeed, in the intestinal mucosa GCs are synthesized in response
to immunological stress. Local GCs then inhibit the activation
of immune cells in a negative feedback leading to the resolution
of inflammation and associated tissue damage (77, 89, 90).
Following anti-CD3 antibody injection, in situ produced GCs
exhibited a regulatory activity on intestinal T cells that are in
close contact with the GC-producing IECs, i.e., IELs and Peyer’s
patches lymphocytes (PPLs) (77). Likewise, infection of mice
with the lymphocytic choriomeningitis virus (LCMV) results
in the activation and expansion of virus-specific intestinal T
cells and the subsequent release of GCs. GCs in turn suppress
anti-viral immune responses. In fact, inhibition of intestinal GC
synthesis accelerated the expansion of antigen-specific cytotoxic
T cells, further confirming the immunoregulatory role of locally
produced GCs (77, 130).
In another study, experimental colitis induction via DSS
or TNBS resulted in epithelial erosion, loss of goblet cells,
and strong immune cell infiltration into the intestinal
mucosa. Simultaneously, it promoted the upregulation of
pro-inflammatory mediators such as TNF, steroidogenic
enzymes and the synthesis of intestinal GCs. Notably and in line
with the discussed role of TNF in the induction of intestinal GC
synthesis, the injection of TNF triggered intestinal GC synthesis
and resulted in the amelioration of oxazolone-induced colitis
in mice. Interestingly, inhibition of intestinal GC synthesis by
metyrapone abrogated the observed anti-inflammatory effect of
TNF (89).
More recently, in a mouse model of DSS-induced colitis, mice
with IEC-specific deletion of the microsomal P450 reductase
enzyme (null mice) exhibited a significant decrease of colonic
GC synthesis compared to wild type mice. This was associated
with an exacerbated colonic inflammation, as evidenced by
the presence of higher levels of pro-inflammatory cytokines,
increased weight loss, colon shortening and colonic tissue
damage in the null mice. Remarkably, restoration of colonic GC
synthesis resulted in amelioration of the colitis (153). This clearly
indicates that intestinal GCs are synthesized as a mechanism to
counterbalance local inflammation. Supporting this notion, the
expression of CYP11A1 and CYP11B1 were robustly reduced in
the inflamed colon biopsies of patients with IBD compared to
healthy controls (138).
Furthermore, intestinal GCs critically regulate the expression
of colonic peroxisome proliferator-activated-receptor-gamma
(PPARγ). PPARγ is a critical regulator of the inflammatory
responses by transrepressing TFs, such as NF-κB and AP-1.
Consequently, disruption of PPARγ expression in mouse colonic
epithelial cells increases susceptibility to DSS-induced colitis.
In line with the anti-inflammatory role of PPARγ, reduced
expression was observed in IBD patients. That also correlated
with a significant reduction in colonic GC synthesis and the
expression of steroidogenic enzymes (140).
We recently demonstrated a significant downregulation of
HSD11B1 gene expression, with a simultaneous upregulation of
HSD11B2, in colons from pediatric IBD patients compared to
healthy controls (96). This opposite transcriptional regulation of
11β-HSD isoenzymes could indicate a possible role of defective
local GC reactivation in the pathogenesis of IBD by limiting
the local levels of the active immunomodulatory GCs, thus
hindering the resolution of inflammation. However, in a murine
model of acute colitis we observed the opposite, where we found
a significant upregulation of Hsd11b1 and a downregulation
of Hsd11b2 upon colitis induction (96). Interestingly, these
correlations were also reported when comparing inflamed tissue
to non-inflamed colonic tissue in IBD patients, suggesting that
dysregulation of the 11β-HSD enzyme system could play a role
in the pathogenesis of IBD (132, 154). Taken together, in view
of the discussed immunoregulatory roles of intestinal GCs, it
is conceivable to believe that defective intestinal GC synthesis
represents a potential key mechanism in the pathogenesis of IBD.
Intestinal GC Synthesis Regulation
Transcriptional Regulation
Whereas, the regulation of adrenal GC synthesis has been
extensively studied and most of the pathways are well-defined,
the molecular pathways for the regulation of extra-adrenal
GC synthesis await further investigation (21). Mueller et al.
investigated the molecular basis of steroidogenesis in the
intestine and found substantial differences in the mode of
regulation of intestinal GC synthesis as compared to the adrenals.
This distinct regulation of intestinal GC synthesis could possibly
reflect an adaptation to the local environment (88). For example,
in marked contrast to the well-known regulatory role of SF-1
in adrenal GC synthesis [reviewed in (26)], SF-1 expression was
found to be absent in the intestine. Interestingly, SF-1 activity was
replaced by its close homolog, the NR liver receptor homolog-1
(LRH-1, NR5A2) (87, 88).
LRH-1 is expressed in tissues derived from endoderm,
including intestine, liver, exocrine pancreas, and the ovary (155).
Moreover, LRH-1 is expressed in macrophages (156) and T cells
(157). LRH-1 plays vital roles in early embryonic development
as evidenced by the embryonically lethal phenotype of the
LRH-1-null mice (158). Other functions of LRH-1 comprise
cholesterol and bile acid homeostasis, glucose metabolism
and steroidogenesis in adulthood (159, 160). In the intestinal
epithelium, LRH-1 contributes to crypt cell proliferation and
epithelial cell renewal through the induction of cell cycle genes,
namely cyclin D1 and cyclin E1 (161). Therefore, LRH-1 has been
suggested as an oncogene and implicated in the development of
colon cancer (162).
LRH-1 is constitutively active, though its function is
regulated by several mechanisms. These include ligand binding,
interactions with co-activators and co-repressors, as well as
posttranslational modifications, such as phosphorylation and
SUMOylation (160, 163, 164). Although LRH-1 is considered
as an orphan NR since no endogenous ligands are identified
yet, phospholipids such as dilauroyl phosphatidylcholine (DLPC)
have been shown to activate LRH-1. Thus, it is very likely that
endogenous ligands exist (165, 166). Among the most studied
co-repressors of LRH-1 is the NR small heterodimer partner
(SHP) (167), which is also a transcriptional target of LRH-1 (168).
Structural studies have shown that SHP preferentially inhibits
LRH-1 over other NRs, including the LRH-1 close homolog SF-1
(169, 170).
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Differences in Regulation of Intestinal vs. Adrenal GC
Synthesis
The differential regulation of intestinal vs. adrenal GC synthesis,
i.e., LRH-1 vs. SF-1, is likely reflecting different needs for the
systemic vs. intestinal GC synthesis (21). In this regard, another
major difference is the differential response of adrenal and
intestinal epithelial cells to cAMP and phorbol myristate acetate
(PMA). In the adrenals, it is well-established that the activation of
ACTH receptors leads to the activation of adenylate cyclase and
the formation of cAMP. In turn, cAMP activates protein kinase
A leading to the induction of steroidogenic enzyme expression.
Surprisingly, cAMP mediated the opposite effect in intestinal
epithelial cells by causing a profound inhibition of both basal and
LRH-1-driven steroidogenesis. Remarkably, a reciprocal effect
was shown upon treatment with PMA that activates protein
kinase C. PMA has been shown to substantially promote both
basal and LRH-1-induced steroidogenic enzymes expression and
GC synthesis in intestinal epithelial cells (88). As PMA is a potent
activator of the MAPK pathway, it is likely that PMA affects
LRH-1 activity by inducing its phosphorylation (21, 171).
LRH-1 Function in Intestinal Homeostasis
In the murine intestinal epithelial cell line mICcl2, that
displays a crypt cell-like phenotype, overexpression of LRH-1
induced the expression of Cyp11a1 and Cyp11b1 in a dose-
dependent manner. This was accompanied by robust induction
of GC synthesis (87). Since LRH-1 is critical for embryonic
development, Mueller et al. used LRH-1 haplodeficient mice
to investigate the role of LRH-1 in the regulation of intestinal
GCs in vivo. They showed that although anti-CD3 injection
strongly induced the expression of Cyp11a1 and Cyp11b1, and
the synthesis of intestinal GCs in wild type mice, it was blunted
in LRH-1 haplodeficient mice. These findings confirm the critical
role of LRH-1 in the regulation of intestinal GC synthesis (87).
In humans, LRH-1 transcriptionally regulates the expression
of the steroidogenic enzymes CYP11A1, CYP17, HSD3B2,
and CYP11B1 as well as StAR (172). The importance of
LRH-1 in the regulation of intestinal GC synthesis and
intestinal immune homeostasis has been demonstrated by
the fact that LRH-1 haplodeficient mice and mice with
intestine-specific deletion of LRH-1 exhibited strongly reduced
GC synthesis, and consequently suffered from exacerbated
colitis (87, 96, 138) (Figure 3). Furthermore, colon biopsies
from patients with IBD show reduced expression of LRH-
1 and steroidogenic enzymes. That was inversely correlated
with the expression of pro-inflammatory cytokines (138).
Additionally, it has been shown that cortisol production and
the expression of LRH-1 and 3β-HSD1 were significantly
decreased in colonic epithelial cells from patients with UC
(140). Recently, we demonstrated a strong correlation between
the expression of LRH-1 and steroidogenic enzymes in
pediatric IBD patients (96). Importantly, we monitored a
significantly reduced expression of HSD11B1 in colons from
IBD patients compared to healthy controls suggesting that
defective reactivation of GCs could represent an underlying
mechanism in intestinal inflammation. Additionally, in a
murine model of colitis we confirmed that colitis-induced
expression of the steroidogenic enzymes Cyp11a1, Cyp11b1,
and Cyp21 is LRH-1-dependent since their induction was
significantly reduced in LRH-1 intestine-specific knockout mice
(96). These data suggest that the presence of LRH-1 protects
the intestinal epithelium against inflammation and underscores
a possible role for defective local GC synthesis in the etiology
of IBD.
Interestingly, SHP inhibits LRH-1-induced Cyp11a1 and
Cyp11b1 expression and GC synthesis in mICcl2 cells (88).
This indicates a potential role of SHP in the regulation of
intestinal immune homeostasis by regulating LRH-1-induced
GC synthesis. Recently, Huang et al. investigated the role of
the NRs SHP and LRH-1 in the regulation of intestinal GC
synthesis and its relevance in intestinal immune homeostasis
in the context of viral infection (130). They showed that
systemic deficiency of SHP results in increased intestinal GC
synthesis during viral infection that suppressed the expansion
and activation of virus-specific T cells. In contrast, intestine-
specific deletion of LRH-1 strongly reduced intestinal GC
synthesis and accelerated the expansion of cytotoxic T cells
upon viral infection (130). Noteworthy, Bayrer et al. recently
showed that intestinal organoids lacking LRH-1 exhibit reduced
expression of the LRH-1 target genes Shp,Cyp11a1, andCyp11b1,
as well as increased crypt cell death and epithelial permeability
(173). They also showed that overexpression of LRH-1 mitigated
inflammation-induced damage of murine and human intestinal
organoids, including those from IBD patients, and decreased the
disease severity in a T cell transfer model of colitis (173).
Of note, the expression of steroidogenic enzymes is linked
to the cell cycle, thus implicating a restriction of the intestinal
GC synthesis to the proliferating cells at the bottom of the
crypts (134, 152). Similar to steroidogenic enzymes, LRH-1
expression is confined to the proliferating cells of the crypts,
suggesting a cell cycle-dependent regulation of intestinal GC
synthesis (87, 134, 161).
LRH-1 seems to contribute to intestinal epithelium
homeostasis via two mechanisms: (1) by stimulating the
synthesis of anti-inflammatory GCs and thereby resolution of
inflammation and associated tissue damage, (2) by enhancing
crypt cell proliferation and hence the regeneration of the
damaged epithelium (Figure 4).
Interestingly, LPS-induced GC synthesis seems not to be
regulated by LRH-1, since it was not affected by LRH-1
deficiency. Surprisingly, LRH-1 haplodeficient mice expressed
even higher levels of Cyp11b1 and showed a tendency toward
increased GC synthesis in response to LPS exposure compared
to wild type mice (89). This clearly indicates that other signals
and TFs are regulating GC synthesis in response to innate
immune system stimulation. Furthermore, TNF has been shown
to suppress LRH-1 and thereby reduce local GC synthesis in
sustained chronic colitis (174).
Of interest is the finding that under basal conditions the
microbiota also contribute to the regulation of intestinal GC
synthesis. Furthermore, intestinal GC synthesis has been shown
to regulate systemic metabolism, indicating a so far unrecognized
role for intestinal GC synthesis in not only regulating local but
also systemic homeostasis (114).
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FIGURE 3 | LRH-1 is critical for intestinal immune homeostasis. Colitis was induced in female 8–9 weeks-old wild type (LRH-1fl/fl) mice and intestine epithelial
cell-specific knockout mice (LRH-1IEC KO) by administration of 2.2% (w/v) DSS in the drinking water for 5 days followed by normal drinking water for 2 days.
Representative H&E staining of Swiss-rolled colon sections of mice treated with DSS at day 7 showing the exacerbated colitis in LRH-1IEC KO mice compared to
LRH-1fl/fl mice. Scale bars: 300µm overview, 150µm inlay.
In summary, despite the well-established roles of TNF and
LRH-1 in the regulation of intestinal GC synthesis, their
interaction in this process is still unclear. It could be possible
that multiple pathways and interaction partners are involved in
LRH-1-regulated intestinal GC synthesis. Moreover, we cannot
exclude that TNF and LRH-1 are acting via independent
mechanisms to stimulate intestinal GC synthesis. Nonetheless,
our understanding of these interactions is far from being
established and other regulatory mechanisms for intestinal GC
synthesis are yet to be defined. It would also be relevant to
investigate the possible crosstalk between local intestinal GCs and
systemic GCs, and how this is regulated.
LRH-1 IN INTESTINAL TUMORS
In the intestinal epithelium, LRH-1 regulates not only
steroidogenesis (87, 89), but also crypt cell proliferation (161).
Thus, LRH-1 has been shown to contribute to intestinal tumor
formation (162) (Figure 4). LRH-1 induces cell proliferation
through the concomitant induction of the cell cycle-regulating
gene products cyclin D1 and E1, and c-Myc, which is further
potentiated by its interaction with β-catenin. Whereas, β-catenin
co-activates LRH-1 after direct binding of LRH-1 to the cyclin
E1 promoter, LRH-1 acts as a co-activator for β-catenin/TCF4 (T
cell factor 4) on the cyclin D1 promoter (161, 162). Due to its role
in proliferation and the maintenance of pluripotency, LRH-1
has emerged as an oncogene implicated in the development
of a variety of cancers, including pancreatic (175), prostate
(176), breast (177, 178), gastric (179), and colorectal cancer
(CRC) (162, 180). LRH-1 exhibited an increased expression
pattern in high-grade prostate cancer, and has been reported
to promote prostate cancer growth by inducing intra-tumoral
steroidogenesis (176). LRH-1 also contributed to metastasis
development in pancreatic cancer (175).
LRH-1 has been shown to drive colon cancer cell growth
by repressing the expression of the cell cycle inhibitor p21
in a p53-dependent manner (180). Consistent with the role
of LRH-1 in CRC development, it has been shown that
LRH-1 heterozygous mice developed significantly less tumors
compared to wild type in two independent models of CRC,
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FIGURE 4 | Role of LRH-1 in healthy colon vs. colon cancer. Left panel: In healthy colon, LRH-1 is expressed in the nucleus of cells at the bottom of the intestinal
crypts, where it regulates intestinal immune homeostasis by the regulation of cell proliferation through cyclins on the one hand, and the synthesis of immunoregulatory
glucocorticoids (GCs) on the other hand. Right panel: In colon cancer, LRH-1 exhibits a nuclear as well as cytoplasmic expression pattern. LRH-1 induces colon
tumor cell proliferation by upregulating expression of cyclins. LRH-1 is proposed to play a role in tumor immune evasion by the synthesis of immunosuppressive GCs
that leads to the inhibition of anti-tumor immune responses. While in healthy tissue SHP imposes a negative feedback loop to LRH-1 signaling, the role of SHP in the
molecular events during colon cancer development remains to be elucidated. SHP, Small heterodimer partner; TILs, tumor infiltrating lymphocytes; Treg, regulatory T
cells; T effector, effector T cells; M1, pro-inflammatory macrophages (anti-tumor); M2, anti-inflammatory (tumor promoting) macrophages.
the azoxymethane-induced and APCmin/+ mice model (162).
Unlike the nuclear expression of LRH-1 at the bottom of the
normal colonic crypts, immunostaining of neoplastic colon from
patients with high-degree dysplasia showed significantly higher
cytoplasmic levels. Additionally, in neoplastic lesions, staining of
LRH-1 was no longer limited to the cells lining the crypts but also
present in the surface epithelial cells (Figure 4). These alterations
in LRH-1 expression and subcellular localization further indicate
the important role of LRH-1 in CRC development (162).
Moreover, if and how the LRH-1-induced SHP, which in healthy
colon tissue counterbalances LRH-1 function, contributes to the
molecular events during colon cancer development, remains
unknown (Figure 4).
In contrast to the known role of LRH-1 in intestinal
tumorigenesis, LRH-1 expression has been shown to be
significantly downregulated in murine adenoma tissue compared
to adjacent normal mucosa. The expression of LRH-1 gene
was reduced in tumors that express elevated levels of the
pro-inflammatory cytokine TNF. Reciprocally, decreased LRH-
1 expression in heterozygous mice attenuates TNF expression
(162). However, the relevance of this inverse correlation is so far
unknown and again points out the complex interaction between
TNF-induced signaling pathways and LRH-1.
Recently, a large CRC patient cohort revealed that
immunohistochemical detection of LRH-1 expression was
drastically enhanced in colon cancer tissue compared to adjacent
non-cancerous tissue from the same patient, and this correlated
with a more advanced disease stage. In fact, patients with positive
LRH-1 expression displayed significantly lower overall survival
rate. Consequently, the authors proposed LRH-1 as a possible
prognostic marker and a novel therapeutic target in CRC (181).
These observations were confirmed in another recent study
that revealed marked overexpression of LRH-1 in CRC tissue
compared to paired non-cancerous tissue (182). Taken together,
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LRH-1 represents a novel and promising therapeutic target for
the treatment of cancer.
INTESTINAL GC SYNTHESIS AS A TUMOR
IMMUNE ESCAPE MECHANISM
The notion that the immune system can recognize and destroy
transformed cells is known as cancer immune surveillance.
However, since the role of the immune system in controlling
cancer growth and recurrence remains highly controversial,
this term has been replaced by “cancer immunoediting” to
describe the dual roles of the immune system in promoting
host defense and facilitating tumor growth and immune escape
(183, 184). Several mechanisms by which cancer cells evade the
immune system have been described. These include: (1) immune
suppression at the tumor microenvironment mediated by Tregs
or other types of suppressive cells (the major mechanism of
tumor immune escape), (2) induction of apoptosis in tumor-
specific cytotoxic T lymphocytes (CTLs) by the expression of
pro-apoptotic ligands e.g., Fas ligand and TRAIL, (3) defective
antigen presentation, (4) release of immunosuppressive cytokines
such as IL-10 and TGFβ, and (5) inducing tolerance and immune
deviation by mechanisms including, among others, shifting the
balance of Th1 immune responses to Th2, and expression
of immune inhibitory molecules such as PD-1 (programmed
death-1) and CTLA-4 (CTL antigen-4) (95, 185).
Colorectal tumors are highly immunogenic. Therefore, anti-
tumor immune responses may significantly limit tumor growth.
In fact, a strong correlation between anti-tumor immune
responses and CRC patient survival has been demonstrated (186–
188). On the other hand, immune escape mechanisms have
been recognized as one of the hallmarks of cancer (123, 189).
Pagés et al. studied the correlation between pathological signs
of early metastatic invasion and the local immune response
within the tumor in a cohort of 959 resected colorectal tumors
using flow cytometry, gene expression profiling and in situ
immunohistochemistry (186). In this study, the authors reported
up to 15 years clinical follow-up of the patients for the presence
or absence of early signs of metastasis. Remarkably, they showed
that tumors without such signs had increased infiltrates of CD8+
T cell numbers and increased gene expression for CD8, T-
box transcription factor 21, interferon regulatory factor 1, IFN-
γ, granulysin, and granzyme B, that correlated with increased
survival. Likewise, the presence of high levels of infiltrating
memory T cells, as measured by immunohistochemistry,
correlated with increased survival (186). The same group
confirmed these results in two other independent cohorts of CRC
patients (187). Furthermore, in 566 CRC patients a significant
positive correlation between markers of innate immune system
and early activated T cells has been linked to protection from
relapse. Additionally increased densities of CTLs and effector
memory T cells within the primary tumor significantly protected
CRC patients from tumor recurrence (188). In another study,
CRC patients with high expression of Th17 markers had a
poor prognosis, whereas patients with high expression of the
Th1 markers had prolonged disease-free survival (190). These
data provide compelling evidence for the role of the immune
system in limiting CRC development and clearly suggest that
immune evasion could represent an important mechanism by
which colorectal tumor cells prevent their destruction by the
immune system.
Supporting this hypothesis, Sidler et al. described the first
evidence for a novel LRH-1-dependent GC synthesis in CRC
cell lines as well as primary tumors, that exerted inhibitory
effects on activated T cells (139). They showed that colon cancer
cell lines express the enzymes required for de novo synthesis
of bioactive GCs, including CYP11A1, CYP11B1, and CYP17.
Consequently, cortisol production as measured by thin layer
chromatography, radioimmunoassay, and bioassay was detected
in culture supernatants (139).
The expression of steroidogenic enzymes in CRC cells
is dependent on endogenous LRH-1, as evidenced by the
diminished expression of these enzymes upon LRH-1
downregulation. Similar to intestinal GC synthesis, tumor-
cell derived GC synthesis was also regulated by LRH-1 since
overexpression of LRH-1 boosted cortisol production in a
dose-dependent manner, whereas it was significantly inhibited
following LRH-1 knockdown. Primary tumors from CRC
patients also expressed high levels of LRH-1, CYP11A1,
CYP11B1, and StAR, and readily synthesized cortisol following
ex vivo culture. Interestingly, unlike the basal inducible GC
production in the normal intestine, LRH-1-mediated GC
synthesis in colonic tumors is constitutive since it was not
further enhanced by PMA (139). This observation suggests
that LRH-1 is constitutively active, or the presence of LRH-1
activators in the tumor microenvironment. Of interest, enhanced
EGF signaling as demonstrated by EGFR overexpression has
been shown in 60–80% of CRC patients, that was associated
with poor prognosis (191). Since EGF has been shown to exert a
mitogenic signal by the MAPK pathway (192), it is tempting to
speculate that EGF-induced signaling pathways activate LRH-1
in CRC tumors via a MAPK-induced phosphorylation. However,
this hypothesis needs to be further investigated.
Noteworthy, tumor-derived GCs suppressed T cell activation,
as shown by the substantial inhibition of CD69 expression
(an early activation marker of T cells) in activated CD4+ and
CD8+ murine splenic T cells. This inhibitory effect was GC-
specific since it was reversed by blocking the GR (139). Hence,
besides its role in inducing tumor cell proliferation, LRH-1
could contribute to CRC tumor development via the synthesis
of immunosuppressive GCs (Figure 4). Taken together, LRH-
1-mediated synthesis of immunoregulatory GCs in CRC could
represent a novel immune escapemechanism by inhibiting T cell-
mediated anti-tumor immune responses and thereby favoring the
tumor growth.
THERAPEUTIC POTENTIAL AND FUTURE
PERSPECTIVE OF INTESTINAL GC
SYNTHESIS
Targeting GCs in Intestinal Inflammation
Thus far, the importance of locally synthesized GCs has been
reflected by the impairment of cortisol production as well as
decreased LRH-1 expression in colonic epithelial cells from UC
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patients (138, 140). Despite the advances in introducing novel
therapies for the treatment of IBD, GCs remain the first-line
treatment for inducing rapid remission in moderate to severe
IBDwith high efficacy. Nevertheless, emergence of resistance and
the side-effects of systemic GCs represent a major therapeutic
challenge (131, 193). Along these lines, restoring local GC
synthesis in the intestine could represent an attractive approach
to ameliorate the symptoms of IBD and to avoid the systemic GC
side-effects. This could be achieved by enhancing LRH-1 activity
in the intestine since LRH-1 controls both local GC synthesis
and epithelial regeneration (87, 89, 90, 138). In fact, a recent
study underlined the therapeutic potential of targeting LRH-1
by showing that restoration of LRH-1 reestablished epithelial
integrity in mouse and human organoids treated with TNF or
5-fluorouracil, a chemotherapeutic agent with intestinal toxicity.
Moreover, overexpression of LRH-1 protected mice from T
cell-induced colitis (173). As mentioned earlier, structure-based
studies identified DLPC as a potential ligand that was able
to enhance LRH-1 transcriptional activity (166). Interestingly,
DLPC has been shown to exert anti-diabetic effects by activating
LRH-1 in the liver when used in a therapeutic setting (194, 195).
Thus, it is tempting to speculate that administration of LRH-1
ligands could also ameliorate intestinal inflammation. However,
this attractive idea remains to be tested.
Targeting GCs in Colorectal Cancer
In CRC, LRH-1 regulates proliferation as well as GC synthesis
that could possibly represents an immune escape mechanism
(139) (Figure 4). In line with this, LRH-1 has also been described
to promote prostate cancer growth by inducing intra-tumoral
steroidogenesis (176).
Consistent with the critical role of LRH-1 in tumor
development, LRH-1 is overexpressed in many tumors, as
discussed above. For instance, a remarkable upregulation of
LRH-1 was reported in CRC tissue compared to paired non-
cancerous tissue from two independent CRC patient cohorts
(181, 182). Hence, suppression of LRH-1 activity in tumors is
postulated to exert anti-proliferative effect that could potentially
lead to tumor regression. Supporting this notion, LRH-1
knockdown resulted in impaired in vitro proliferation of
pancreatic and CRC cell lines (175, 196). Recently, Qu et al.
showed that targeting LRH-1 via microRNA inhibited in vitro
proliferation and invasion of CRC cell lines (182). These data
provide compelling evidence for the therapeutic potential of
targeting LRH-1 in cancer. Advances in structure-based studies
identified small molecule inhibitors of LRH-1 including 3d2
(197) and SR1848 (198). The inhibitory effect of 3d2 and SR1848
on LRH-1 was confirmed in vitro and in vivo and reported to
induce anti-proliferative effects on a variety of cancer cell lines
(157, 197, 198).
In conclusion, inhibition of LRH-1 activity in colon tumors
with high LRH-1 expression represents an interesting therapeutic
approach to be followed upon, aiming at inhibition of both
LRH-1-induced proliferation as well as GC synthesis. This is of
particular interest since in CRC a strong correlation between
the degree of immune cell infiltrates and patient survival
has been demonstrated (186, 187). Of note, ex vivo culture
of primary colonic tumors from patients showed increased
GC synthesis compared to adjacent non-tumor tissue (139).
These observations further underscore that immune evasion,
e.g., via the synthesis of immunoregulatory GCs, might be
an important mechanism by which intestinal tumors shape
the tumor microenvironment resulting on one hand in tumor
support by stromal cells, on the other hand in the escape of CRC
from the destruction by the immune system.
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